Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3ET7S | ISIN: CA47817E1034 | Ticker-Symbol: JNJ0
Frankfurt
06.06.25 | 08:07
12,500 Euro
0,00 % 0,000
Branche
Konsumgüter
Aktienmarkt
Sonstige
1-Jahres-Chart
JOHNSON & JOHNSON CDR Chart 1 Jahr
5-Tage-Chart
JOHNSON & JOHNSON CDR 5-Tage-Chart

Aktuelle News zur JOHNSON & JOHNSON CDR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
00:46J&J's Growth Strategy in Lung Cancer Borrows From Its Experience in Multiple Myeloma6
Do12 Analysts Have This To Say About Johnson & Johnson11
MiJ&J sends AnaptysBio lower with mid-stage trial data for anti-inflammatory agent6
MiJNJ's Combo Therapy Shows Strong Phase III Efficacy in Prostate Cancer4
JOHNSON & JOHNSON CDR Aktie jetzt für 0€ handeln
DiJohnson & Johnson Highlights Multiple Blood Cancer Trial Data At ASCO Presentation3
DiFormer Johnson & Johnson MedTech CIO joins Microsoft4
DiJohnson & Johnson's DARZALEX FASPRO Improves Myeloma Survival And MRD Response Rates299NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) shared new findings at the 2025 ASCO Annual Meeting from two Phase 3 studies, PERSEUS and CEPHEUS, highlighting the long-term benefits of a...
► Artikel lesen
DiJohnson & Johnson Says Carvykti Achieved Treatment-free Remissions For 5 Years In Myeloma Patients309NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) announced Tuesday new long-term follow-up data from the Phase 1b/2 Cartitude-1 study demonstrating 33 percent of patients in the study with...
► Artikel lesen
DiASCO: J&J highlights Rybrevant-Lazcluze combo in 'Breathtaking Moments' lung cancer campaign high over Chicago skyline3
DiJohnson & Johnson's Trispecific Antibody Show Promising Response In Myeloma Patients277NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) announced Tuesday initial Phase 1 results of JNJ-79635322 (JNJ-5322), a novel investigational trispecific antibody (TsAb) in patients with relapsed...
► Artikel lesen
DiJNJ-5322 shows promise in multiple myeloma Phase 1 trial6
DiJNJ-5322 zeigt vielversprechende Ergebnisse in Phase-1-Studie bei Multiplem Myelom3
DiJ&J data support earlier use of combo pill in prostate cancer6
DiJohnson & Johnson: DARZALEX FASPRO (daratumumab and hyaluronidase-fihj)-based regimen shows 95 percent progression-free survival at four years in transplant-eligible, newly diagnosed patients with multiple myeloma who achieved ...80More than half of patients maintained minimal residual disease (MRD) negativity (10-5) with DARZALEX FASPRO® for 24 months or longer in the Phase 3 PERSEUS study Data...
► Artikel lesen
DiJohnson & Johnson: Single infusion of CARVYKTI (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma117New long-term CARTITUDE-1 data show one-third of patients treated with CARVYKTI® remain progression-free CARTITUDE-4 analysis shows compelling overall survival...
► Artikel lesen
DiJohnson & Johnson: Early results from trispecific antibody show promising response in heavily pretreated multiple myeloma patients99Phase 1 trial demonstrates encouraging clinical activity of investigational immunotherapy for relapsed or refractory multiple myeloma Novel investigational dual-antigen-targeting...
► Artikel lesen
DiJohnson & Johnson Reports Positive Results From Phase 3 AMPLITUDE Study In Prostate Cancer257NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) Tuesday reported encouraging results from the Phase 3 AMPLITUDE study evaluating the combination of niraparib and abiraterone acetate (Akeega)...
► Artikel lesen
DiJ&J posts late-stage trial win for PARP inhibitor combo in prostate cancer5
DiJohnson & Johnson MedTech launches new Kincise 2 automated hip, knee surgical system3
DiJohnson & Johnson leads with first PARP inhibitor combo to improve efficacy in patients with HRR-altered mCSPC103Results from the Phase 3 AMPLITUDE study show the potential of AKEEGA® (niraparib and abiraterone acetate dual-action tablet) to delay cancer progression and worsening...
► Artikel lesen
Weiter >>
760 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1